â Registrational cohort enrollment in RESET-Myositisâą trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis â
Related Questions
What are the revenue, net loss, and cash burn figures for Q2 2025, and how do they compare to consensus estimates?
How does Cabaletta Bio's valuation (e.g., EV/EBITDA, marketâcap multiples) compare to peers in the rareâdisease/biotech sector?
How much cash runway does Cabaletta Bio have, and are there plans for additional financing before the BLA submission?
How does the sentiment score of 35 influence market perception, and have analysts adjusted their ratings or price targets?
What are the potential dilution effects from any planned equity raises or option exercises?
How does the expected 2027 BLA submission timeline for rese-cel compare with competitors' pipelines in the myositis space?
Are there any partnership or licensing opportunities tied to the RESETâMyositis trial that could impact the stock?
Will the enrollment start in 2H25 affect shortâterm stock volatility, and what are the expected nearâterm catalysts?
What are the key risks associated with the registrational cohort enrollment timeline for the RESETâMyositis trial?
What is the total addressable market and potential revenue for rese-cel if approved for myositis?